Ke Wang1, Leila R Zelnick1, Peter B Imrey2,3, Ian H deBoer1, Jonathan Himmelfarb1, Michael D Allon4, Alfred K Cheung5,6,7,8, Laura M Dember9,10, Prabir Roy-Chaudhury11,12, Miguel A Vazquez13, John W Kusek14, Harold I Feldman9,10, Gerald J Beck2,3, Bryan Kestenbaum1. 1. Department of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA. 2. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. 3. Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA. 4. Division of Nephrology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA. 5. Division of Nephrology and Hypertension, Salt Lake City, Utah, USA. 6. Department of Bioengineering, University of Utah School of Medicine, Salt Lake City, Utah, USA. 7. Renal Section, Medical Service, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah, USA. 8. Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, China. 9. Renal-Electrolyte and Hypertension Division, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 10. Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 11. Division of Nephrology, University of Arizona Health Sciences and Banner University Medical Center, Tucson, Arizona, USA. 12. Medical Service, Southern Arizona Veterans Affairs Healthcare System, Tucson, Arizona, USA. 13. Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 14. Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
Abstract
BACKGROUND: The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis. However, approximately half of AVFs fail to mature. The use of angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs) exerts favorable endothelial effects and may promote AVF maturation. We tested associations of ACE-I and ARBs, CCBs, beta-blockers, and diuretics with the maturation of newly created AVFs. METHODS: We evaluated 602 participants from the Hemodialysis Fistula Maturation Study, a multi-center, prospective cohort study of AVF maturation. We ascertained the use of each medication class within 45 days of AVF creation surgery. We defined maturation outcomes by clinical use within 9 months of surgery or 4 weeks of initiating hemodialysis. RESULTS: Unassisted AVF maturation failure without intervention occurred in 54.0% of participants, and overall AVF maturation failure (with or without intervention) occurred in 30.1%. After covariate adjustment, CCB use was associated with a 25% lower risk of overall AVF maturation failure (95% CI 3%-41% lower) but a non-significant 10% lower risk of unassisted maturation failure (95% CI 23% lower to 5% higher). ACE-I/ARB, beta-blocker, and diuretic use was not significantly associated with AVF maturation outcomes. None of the antihypertensive medication classes were associated with changes in AVF diameter or blood flow over 6 weeks following surgery. CONCLUSIONS: CCB use may be associated with a lower risk of overall AVF maturation failure. Further studies are needed to determine whether CCBs might play a causal role in improving AVF maturation outcomes.
BACKGROUND: The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis. However, approximately half of AVFs fail to mature. The use of angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs) exerts favorable endothelial effects and may promote AVF maturation. We tested associations of ACE-I and ARBs, CCBs, beta-blockers, and diuretics with the maturation of newly created AVFs. METHODS: We evaluated 602 participants from the Hemodialysis Fistula Maturation Study, a multi-center, prospective cohort study of AVF maturation. We ascertained the use of each medication class within 45 days of AVF creation surgery. We defined maturation outcomes by clinical use within 9 months of surgery or 4 weeks of initiating hemodialysis. RESULTS: Unassisted AVF maturation failure without intervention occurred in 54.0% of participants, and overall AVF maturation failure (with or without intervention) occurred in 30.1%. After covariate adjustment, CCB use was associated with a 25% lower risk of overall AVF maturation failure (95% CI 3%-41% lower) but a non-significant 10% lower risk of unassisted maturation failure (95% CI 23% lower to 5% higher). ACE-I/ARB, beta-blocker, and diuretic use was not significantly associated with AVF maturation outcomes. None of the antihypertensive medication classes were associated with changes in AVF diameter or blood flow over 6 weeks following surgery. CONCLUSIONS: CCB use may be associated with a lower risk of overall AVF maturation failure. Further studies are needed to determine whether CCBs might play a causal role in improving AVF maturation outcomes.
Authors: Michael Allon; Tom Greene; Laura M Dember; Joseph A Vita; Alfred K Cheung; Naomi M Hamburg; Peter B Imrey; James S Kaufman; Michelle L Robbin; Yan-Ting Shiu; Christi M Terry; Heidi R Umphrey; Harold I Feldman Journal: J Am Soc Nephrol Date: 2016-05-09 Impact factor: 10.121
Authors: Bryan Kestenbaum; Daniel L Gillen; Donald J Sherrard; Steven Seliger; Adrianne Ball; Catherine Stehman-Breen Journal: Kidney Int Date: 2002-06 Impact factor: 10.612
Authors: Michael Allon; Michelle L Robbin; Carlton J Young; Mark H Deierhoi; Jeremy Goodman; Michael Hanaway; Mark E Lockhart; Silvio Litovsky Journal: Clin J Am Soc Nephrol Date: 2013-06-27 Impact factor: 8.237
Authors: Patrizia Cristofori; Federica Crivellente; Mario Campagnola; Anna Fratta Pasini; Ulisse Garbin; Anna Rigoni; Maria Tosetti; John Turton; Ivo Faustinelli; Luciano Cominacini Journal: Int J Exp Pathol Date: 2004-04 Impact factor: 1.925
Authors: Christoph B Olivier; Vandana Sundaram; Glenn M Chertow; Sumana Shashidhar; Lori K McDonnell; Victoria Y Ding; Manisha Desai; Kenneth W Mahaffey; Matthew Mell Journal: J Vasc Access Date: 2019-11-27 Impact factor: 2.283